Filtered By:
Infectious Disease: Gastroenteritis
Drug: Temodar
This page shows you your search results in order of date.
Order by Relevance | Date
Total 5 results found since Jan 2013.
Regulatory Issues: PMDA - Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma
Oncologist. 2023 Mar 14:oyad041. doi: 10.1093/oncolo/oyad041. Online ahead of print.ABSTRACTIn June 2021, the Ministry of Health, Labor and Welfare approved Delytact Injection as a regenerative medical product for oncolytic virus therapy. The active substance of Delytact Injection is teserpaturev, a genetically engineered herpes simplex virus type 1 (strain F) in which the α47 gene and both copies of the γ34.5 gene have been deleted and the infected cell protein 6 (ICP6) gene has been inactivated by the insertion of the lacZ gene from Escherichia coli. Delytact Injection, when intratumorally administered to patients with...
Source: The Oncologist - March 14, 2023 Category: Cancer & Oncology Authors: Yoshiaki Maruyama Akira Sakurai Shinichi Noda Yasuhiro Fujiwara Narumi Okura Toshinori Takagi Junichi Asano Futaba Honda Source Type: research
